The past few years have been tough for biotech, with many companies grappling with down rounds or major funding challenges.

As we step into 2025, the big question is:

How should you approach fundraising in this market?

• Should you hold off and wait for a recovery?
• Or is there a smarter way to navigate the current landscape?

Let’s explore! 👋